Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma

被引：0
|
作者：
Han, Kelong [1 ]
Ren, Melanie [2 ]
Wick, Wolfgang [3 ,4 ]
Abrey, Lauren [5 ]
Das, Asha [1 ]
Jin, Jin [1 ]
Reardon, David A. [6 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Stanford Univ, Palo Alto, CA 94304 USA
[3] Univ Med Ctr, Heidelberg, Germany
[4] DKFZ, Heidelberg, Germany
[5] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
NEURO-ONCOLOGY | 2015年 / 17卷 / 05期
关键词：
TRIALS;
D O I：
10.1093/neuonc/nov021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：764 / 765
页数：2
相关论文
共 50 条
  • [1] Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
    Han, Kelong
    Ren, Melanie
    Wick, Wolfgang
    Abrey, Lauren
    Das, Asha
    Jin, Jin
    Reardon, David A.
    [J]. NEURO-ONCOLOGY, 2014, 16 (05) : 696 - 706
  • [2] Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
    Sjoquist, Katrin M.
    Lord, Sarah J.
    Friedlander, Michael L.
    Simes, Robert John
    Marschner, Ian C.
    Lee, Chee Khoon
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10 : 1 - 16
  • [3] META-ANALYSIS OF THE VALIDITY OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER TRIALS
    Chirila, C.
    Odom, D. M.
    Devercelli, G.
    Khan, S.
    Sherif, B. N.
    Kaye, J. A.
    Molnar, I.
    Sherrill, B. H.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 202 - 202
  • [4] Progression-free survival as a surrogate endpoint for hazard ratio and median overall survival in glioblastoma: A literature-based meta-analysis from 91 trials
    Han, K.
    Ren, M.
    Wick, W.
    Jin, J.
    Abrey, L.
    Das, A.
    Reardon, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S775 - S776
  • [5] INVESTIGATING PROGRESSION-FREE SURVIVAL AS A POTENTIAL SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN FIRST-LINE TREATMENT FOR GLIOBLASTOMA MULTIFORME: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Fu, A.
    Fazeli, M. S.
    Kanters, S.
    Siliman, G.
    Ma, Chaudhary
    Gogate, A.
    Kurt, M.
    [J]. VALUE IN HEALTH, 2020, 23 : S4 - S4
  • [6] EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER: SYSTEMATIC REVIEW AND TRIAL LEVEL META-ANALYSIS
    Adunlin, G.
    Dranitsaris, G.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A170 - A170
  • [7] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
  • [8] Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
    Paoletti, Xavier
    Oba, Koji
    Bang, Yung-Jue
    Bleiberg, Harry
    Boku, Narikazu
    Bouche, Olivier
    Catalano, Paul
    Fuse, Nozomu
    Michiels, Stefan
    Moehler, Markus
    Morita, Satoshi
    Ohashi, Yasuo
    Ohtsu, Atsushi
    Roth, Arnaud
    Rougier, Philippe
    Sakamoto, Junichi
    Sargent, Daniel
    Sasako, Mitsuru
    Shitara, Kohei
    Thuss-Patience, Peter
    Van Cutsem, Eric
    Burzykowski, Tomasz
    Buyse, Marc
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21) : 1667 - 1670
  • [9] Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
    Hughes, Michael D.
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2008, 17 (05) : 487 - 495
  • [10] Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials
    Trippa, Lorenzo
    Wen, Patrick Y.
    Parmigiani, Giovanni
    Berry, Donald A.
    Alexander, Brian M.
    [J]. NEURO-ONCOLOGY, 2015, 17 (08) : 1106 - 1113
12345